Two years ago! That was the last time you could buy shares of Recursion Pharmaceuticals (NASDAQ: RXRX) at today's price! Here's why!

 

Recursion Pharmaceuticals (NASDAQ: RXRX) 

recently raised approximately $200 million through a public offering of 30,769,230 shares of its Class A common stock at a price of $6.50 per share.

The lead book-running managers for this offering were Goldman Sachs & Co. LLC and J.P. Morgan, with Allen & Company LLC also acting as a book-running manager​ (Recursion Pharmaceuticals, Inc.)​​ (Market Wire News)​.

The specific buyers of these shares include institutional investors, as is typical in such offerings.

 Recursion's institutional ownership is notably high, with major investors including firms like Kinnevik AB, which holds a significant portion of shares. 

Other institutional investors involved over the last year include DNB Asset Management AS, Teachers Retirement System of the State of Kentucky, and California State Teachers Retirement System​ (Stock Market News Live | Stock Titan)​​ (MarketBeat)​.

These funds are expected to support Recursion's ongoing research and development efforts, leveraging their platform for drug discovery. This move is a strategic effort to secure additional capital necessary for advancing their clinical programs and expanding their operational capabilities​ (Recursion Pharmaceuticals, Inc.)​​ (Market Wire News)​​ (Stock Market News Live | Stock Titan)​.

also...

Nvidia owns shares in Recursion Pharmaceuticals (RXRX). 

Nvidia made a significant investment of $50 million in Recursion in July 2023, purchasing shares through a private investment in public equity (PIPE). 

As part of this investment, Nvidia acquired approximately 7.7 million shares of Recursion, which at the time was valued at $75.9 million​ (MarketBeat)​​ (Recursion Pharmaceuticals, Inc.)​​ (Ground News)​. 

This investment underscores Nvidia's confidence in Recursion's AI-driven drug discovery platform and represents a strategic partnership to leverage Nvidia's computing capabilities in the biotech field.

Financials

Recursion Pharmaceuticals is currently in a strong financial position with $296.3 million in cash and cash equivalents as of March 31, 2024 and with this recent infusion of cash, they have basically doubled their financial position.

 The company reported a revenue of $13.8 million for Q1 2024, primarily due to its partnership with Roche. However, they also posted a net loss of $91.4 million for the quarter due to significant investments in research and development and general administrative expenses. 

Technologically

Recursion continues to enhance its platform, focusing on advanced computational biology, machine learning, and transcriptomics to drive drug discovery​ (Recursion Pharmaceuticals, Inc.)​.

Discl: Long $RXRX and accumulating!

"The rapid and complete resolution of aggressive MSS colorectal cancer tumors observed in this study is unprecedented in the field" says the author Dr. Kasi

In Bio Science, there is a race for better Gene sequencing and genomics technology!

Often called the "Google" of Blockchain technology, "The Graph (GRT) has a unique place and usefulness in the Crypto universe!

 

If interested in blockchain technology and considering buying a useful cryptocurrency, one might consider purchasing GRT (The Graph) for several compelling reasons:

1. Fundamental Use Case:

   • Data Indexing and Querying: The Graph provides a crucial service by indexing and querying blockchain data efficiently using GraphQL. This is essential for many decentralized applications (dApps) that require real-time data from blockchains like Ethereum.

2. Wide Adoption:

   • Support from Major Projects: The Graph is used by numerous high-profile dApps and DeFi platforms, such as Uniswap, Aave, and Synthetix. This widespread adoption demonstrates its utility and reliability within the blockchain ecosystem​ (CoinTelegraph)​​ (Finbold)​.

3. Decentralization and Governance:

   • Community-Driven: The Graph operates with a decentralized model involving indexers, curators, and delegators, all incentivized through the GRT token. This model ensures the network's robustness and reliability, fostering a trust-based environment​ (CoinTelegraph)​.

4. Ecosystem Expansion:

   • Multi-Chain Support: While initially focused on Ethereum, The Graph has been expanding to support other blockchains, enhancing its interoperability and potential use cases across different blockchain ecosystems​ (Finbold)​.

5. Active Development and Community:

   • Continuous Improvement: The Graph has an active development team and community contributing to its ongoing improvement and expansion. This active engagement is crucial for the long-term viability and innovation of the platform​ (CoinTelegraph)​.

6. Investment Potential:

   • Growth Prospects: Given its fundamental role in the blockchain ecosystem and growing adoption, GRT has significant growth potential. The expansion into new blockchains and continuous feature enhancements could drive its demand and value over time.

7. Strategic Partnerships:

   • Collaborations: The Graph's partnerships with various blockchain projects and integration into many decentralized finance (DeFi) protocols indicate strong industry support and potential for future growth.

8. Market Position:

   • Established Player: As an established player in the blockchain data indexing space, The Graph holds a unique position that can be pivotal as the blockchain ecosystem continues to grow and evolve.

Considering these points, GRT represents a valuable addition to a blockchain-focused investment portfolio. It provides a utility that is integral to the operation and efficiency of many blockchain applications, making it a fundamentally strong choice for someone interested in blockchain technology.

However, as with any investment, it is essential to conduct thorough research and consider market conditions, project updates, and broader economic factors before making a decision.

Discl: Picked up some $GRT under .25c per

As of July 2024, the top ten most valuable cryptocurrencies by market capitalization are:

1. Bitcoin (BTC): The original and most valuable cryptocurrency, known for its role as a store of value and its decentralized nature. Market cap: $1.25 trillion.

2. Ethereum (ETH): Known for its smart contract functionality, Ethereum is a leading platform for decentralized applications (dApps). Market cap: $369.7 billion.

3. Tether (USDT): A stablecoin pegged to the US dollar, widely used for trading and transactions due to its stable value. Market cap: $110.9 billion.

4. BNB (Binance Coin): Utilized within the Binance ecosystem for various applications, including transaction fee discounts on the Binance exchange. Market cap: $86.79 billion.

5. XRP (Ripple): Facilitates cross-border payments and currency exchanges efficiently, used by financial institutions worldwide. Market cap: $28 billion.

6. Solana (SOL): A high-performance blockchain supporting decentralized apps and finance, known for its speed and low transaction costs. Market cap: $72 billion.

7. USD Coin (USDC): Another stablecoin pegged to the US dollar, USDC is popular for its reliability in global transactions. Market cap: $33.3 billion.

8. Cardano (ADA): A blockchain platform for smart contracts and decentralized applications, focusing on sustainability and scalability. Market cap: $16.2 billion.

9. Dogecoin (DOGE): Initially started as a meme coin, Dogecoin has gained substantial popularity and usage, particularly for tipping and charity donations. Market cap: $14 billion.

10. Polkadot (DOT): Enables interoperability between different blockchains, aiming to create a decentralized internet of blockchains. Market cap: $13 billion.

These cryptocurrencies are noted for their significant market caps and the unique functionalities they bring to the blockchain ecosystem​ (BeInCrypto)​​ (Nasdaq)​.

Domains are a 21st Century Investment!

Xomains.com